NFE2L2 and lung adenocarcinoma: In addition, aberrations (mutations and amplifications) in the transcription factor NFE2L2 in six different tumour types (BLCA, head and neck squamous cell carcinoma, kidney renal clear cell carcinoma, lung adenocarcinoma, LUSC and UCEC) exhibited trans-effects on gene expression (P(D)≥0.8).